NCT04243785View on ClinicalTrials.gov

A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

PHASE1RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

January 6, 2020

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2027

Conditions
Acute Myeloid LeukemiaMyelodysplastic Syndrome
Interventions
DRUG

BTX-A51

Orally administered capsules available in strengths of 0.5 mg, 1.0 mg, 2.0 mg and 7 mg.

DRUG

Azacitidine

Azacitidine will be administered IV or SC 75 mg/m2 QD on Days 1-7 of each 28-day cycle.

Trial Locations (3)

10065

RECRUITING

Memorial Sloan-Kettering Cancer Center, New York

77030

RECRUITING

The University of Texas MD Anderson Cancer Center, Houston

91010

RECRUITING

City of Hope National Medical Center, Duarte

Sponsors
All Listed Sponsors
lead

Edgewood Oncology Inc.

INDUSTRY